Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrantoin SCHEMBL29582305 | 0.89 | TSHR (0.54) | TSHRTDP1CRBNAKR1B1ALDH1A1 | |
| Tetrantoin SCHEMBL79518 | 0.89 | TSHR (0.54) | TSHRTDP1CRBNAKR1B1ALDH1A1 | |
| SCHEMBL13791964 | 0.82 | ATM (0.37) | TSHRTDP1AKR1B1ALDH1A1 | |
| SCHEMBL12199729 | 0.80 | TSHR (0.57) | TSHRTDP1CRBNAKR1B1CACNA1F | |
| SCHEMBL13055192 | 0.80 | CALCRL (0.44) | AKR1B1ALDH1A1MAPTCALCRLPDE7A | |
| SCHEMBL23857468 | 0.79 | PDE7A (0.44) | TSHRTDP1CRBNAKR1B1DDB1 | |
| SCHEMBL7927641 | 0.79 | PDE7A (0.43) | TSHRTDP1CRBNAKR1B1DDB1 | |
| SCHEMBL7918149 | 0.79 | PDE7A (0.42) | TSHRTDP1CRBNAKR1B1DDB1 | |
| SCHEMBL13192017 | 0.78 | TDP2 (0.42) | TSHRTDP1CRBNCALCRLPDE7A | |
| SCHEMBL1727271 | 0.78 | TDP2 (0.42) | AKR1B1CALCRLPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344158-A1 | Use of isoQC inhibitors | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | claimed |
| EP-2846798-B1 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| EP-2846801-B1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2846801-B1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| EP-2686324-B1 | PIPERIDINE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-1613368-A2 | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1608627-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1606286-A2 | BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606264-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1605936-A1 | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087649-A2 | BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004082605-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004082678-A1 | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083187-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004082602-A2 | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | TSHR 2416/4885TDP1 3174/4885CRBN 4215/4885 |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TSHR 229/4885TDP1 4417/4885CRBN 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.